C. Morgan

发表

Gender differences in patients with stable angina attending primary care practices.

R. Dreyer, M. Arstall, R. Tavella, 2011, Heart, lung & circulation.

Fractures in children with Pompe disease: a potentiallong-term complication

D. Frush, Yuan-Tsong Chen, C. Morgan, 2007, Pediatric Radiology.

In patients with chronic stable angina, secondary prevention appears better in the very old compared to younger patients: the Coronary Artery Disease in gENeral practiCE (CADENCE) Substudy.

R. Tavella, C. Morgan, A. Weekes, 2013, Heart, lung & circulation.

Quality of Life of Patients With Peripheral Arterial Disease and Chronic Stable Angina

R. Tavella, C. Morgan, A. Weekes, 2012, Angiology.

Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease

C. Morgan, Jennifer S. Li, D. K. Benjamin, 2008, Genetics in Medicine.

A randomized study of alglucosidase alfa in late-onset Pompe's disease.

A. Pestronk, P. Laforêt, C. Morgan, 2010, The New England journal of medicine.

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.

A. Pestronk, J. Charrow, H. Plotkin, 2012, Molecular genetics and metabolism.

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

B. Byrne, H. Mandel, N. Leslie, 2009, Genetics in Medicine.

Cardiac arrhythmias following anesthesia induction in infantile‐onset Pompe disease: a case series

A. Ross, C. Morgan, Jennifer S. Li, 2007, Paediatric anaesthesia.

Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease

J. Clancy, H. Mandel, N. Leslie, 2009, Pediatric Research.

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.

J. De Sutter, R. Peters, S. Wiedmann, 2019, Atherosclerosis.

The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study.

J. Spertus, R. Tavella, C. Morgan, 2009, Archives of internal medicine.

Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study

C. Anderson, A. Cass, F. Turnbull, 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study)

A. Cass, J. Chalmers, Anushka Patel, 2010, The Medical journal of Australia.

A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases

C. Morgan, L. Ottesen, R. Verheijen, 2020, Pharmaceutical Medicine.

Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease

J. Clancy, J. Charrow, C. Tifft, 2015, Neuromuscular Disorders.

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.

A. Pestronk, J. Charrow, H. Plotkin, 2012, Molecular Genetics and Metabolism.

Letter to the Editors: Concerning “CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy” by Al Khallaf et al

C. Morgan, A. Rosenberg, P. Kishnani, 2014, Journal of Inherited Metabolic Disease.

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.

J. De Sutter, R. Peters, S. Wiedmann, 2019, Atherosclerosis.